Development of a Humanized Antibody with High Therapeutic Potential against Dengue Virus Type 2 Pi-Chun Li1,2, Mei-Ying Liao2, Ping-Chang Cheng2, Jian-Jong Liang3, I-Ju Liu2, Chien-Yu Chiu2, Yi-Ling Lin3, Gwong-Jen J. Ch

First Page		Document Content
Date: 2014-10-02 03:12:04 Immunology Antibody-dependent enhancement Monoclonal antibodies Dengue virus Dengue fever Human anti-mouse antibody Hybridoma technology Humanized antibody Flavivirus Biology Medicine Immune system		Development of a Humanized Antibody with High Therapeutic Potential against Dengue Virus Type 2 Pi-Chun Li1,2, Mei-Ying Liao2, Ping-Chang Cheng2, Jian-Jong Liang3, I-Ju Liu2, Chien-Yu Chiu2, Yi-Ling Lin3, Gwong-Jen J. Ch Add to Reading List Source URL: stacks.cdc.gov Download Document from Source Website File Size: 2,31 MB Share Document on Facebook

	Visterra to Present Data at ICAAC on VIS513, its Humanized Monoclonal Antibody That Targets a Conserved Site on the Dengue Virus E Protein ‒ VIS513 engineered to bind and potently neutralize all four serotypes of dengu DocID: 1v1w4 - View Document
	Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT – Expands Company’s Therapeutic Pipeline for Infectious Diseases – Cambridge, MA – December 2, 2013 – Visterra, DocID: 1ujGa - View Document
	Frequently Asked Questions: Zika Virus 1. What is Zika virus? Zika fever is a mild illness caused by a mosquito-borne virus similar to those that cause dengue and chikungunya virus infection. It has been identified in se DocID: 1tooG - View Document
	University of Puerto Rico Medical Sciences Campus Caribbean Primate Research Center Secondary Zika virus infection do not support evidences of Antibody-Dependent Enhancement in vivo in dengue pre-exposed rhesus macaques DocID: 1sT3H - View Document
	ZOOTAXA 589 Pictorial keys for the identification of mosquitoes (Diptera: Culicidae) associated with Dengue Virus Transmission LEOPOLDO M. RUEDA DocID: 1sqlQ - View Document